Giacomo Bianchi

Dr. Giacomo Bianchi

Dipartimento Cardio-Toraco-Vascolare, University of Siena, Siena, Tuscany, Italy
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
SMSilvia Mariani
Silvia Mariani
SHSam Heuts
Sam Heuts
BBBas Van Bussl
Bas Van Bussl
Michele Di MauroMichele Di Mauro
Michele Di Mauro
Dominik WiedemannDominik Wiedemann
Dominik Wiedemann
MSMarco Solinas
Marco Solinas
Background: Extracorporeal membrane oxygenation (ECMO) has been increasingly used for postcardiotomy cardiogenic shock, but without a concomitant reduction in observed in‐hospital mortality. Long‐term outcomes are unknown. This study describes patients’ characteristics, in‐hospital outcome, and 10‐year survival after postcardiotomy ECMO. Variables associated with in‐hospital and postdischarge mortality are investigated and reported. Methods and Results: The retrospective international multicenter observational PELS‐1 (Postcardiotomy Extracorporeal Life Support) study includes data on adults requiring ECMO for postcardiotomy cardiogenic shock between 2000 and 2020 from 34 centers. Variables associated with mortality were estimated preoperatively, intraoperatively, during ECMO, and after the occurrence of any complications, and then analyzed at different time points during a patient's clinical course, through mixed Cox proportional hazards models containing fixed and random effects. Follow‐up was established by institutional chart review or contacting patients. This analysis included 2058 patients (59% were men; median [interquartile range] age, 65.0 [55.0–72.0] years). In‐hospital mortality was 60.5%. Independent variables associated with in‐hospital mortality were age (hazard ratio [HR], 1.02 [95% CI, 1.01–1.02]) and preoperative cardiac arrest (HR, 1.41 [95% CI, 1.15–1.73]). In the subgroup of hospital survivors, the overall 1‐, 2‐, 5‐, and 10‐year survival rates were 89.5% (95% CI, 87.0%–92.0%), 85.4% (95% CI, 82.5%–88.3%), 76.4% (95% CI, 72.5%–80.5%), and 65.9% (95% CI, 60.3%–72.0%), respectively. Variables associated with postdischarge mortality included older age, atrial fibrillation, emergency surgery, type of surgery, postoperative acute kidney injury, and postoperative septic shock. Conclusions: In adults, in‐hospital mortality after postcardiotomy ECMO remains high; however, two‐thirds of those who are discharged from hospital survive up to 10 years. Patient selection, intraoperative decisions, and ECMO management remain key variables associated with survival in this cohort. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03857217.

1 January 2018 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
Giovanni ConcistreGiovanni Concistre
Giovanni Concistre
FCFrancesca Chiaramonti
Francesca Chiaramonti
Giacomo BianchiGiacomo Bianchi
Giacomo Bianchi
ACAlfredo Giuseppe Cerillo
Alfredo Giuseppe Cerillo
MMMichele Murzi
Michele Murzi
MSMarco Solinas
Marco Solinas

3 April 2010 in Heart Failure Reviews
Verified
Journal Article
Closed access
PDF file
Vincenzo LionettiVincenzo Lionetti
Vincenzo Lionetti
Giacomo BianchiGiacomo Bianchi
Giacomo Bianchi
FRFabio A. Recchia
Fabio A. Recchia
Carlo VenturaCarlo Ventura
Carlo Ventura

1 September 2012 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
YZYunshan Zhao
Yunshan Zhao
TLTieluo Li
Tieluo Li
XWXufeng Wei
Xufeng Wei
Giacomo BianchiGiacomo Bianchi
Giacomo Bianchi
JHJingping Hu
Jingping Hu
BGBartley P. Griffith
Bartley P. Griffith
Progressive cardiac remodeling, including the myopathic process in the adjacent zone following myocardial infarction (MI), contributes greatly to the development of cardiac failure. Cardiomyoplasty using bone marrow-derived mesenchymal stem cells (MSCs) has been demonstrated to protect cardiomyocytes and/or repair damaged myocardium, leading to improved cardiac performance, but the therapeutic effects on cardiac remodeling are still under investigation. Here, we tested the hypothesis that MSCs could improve the pathological remodeling of the adjacent myocardium abutting the infarct. Allogeneic ovine MSCs were transplanted into the adjacent zone by intracardiac injection 4 hours after infarction. Results showed that remodeling and contractile strain alteration were reduced in the adjacent zone of the MSC-treated group. Cardiomyocyte hypertrophy was significantly attenuated with the normalization of the hypertrophy-related signaling proteins phosphatidylinositol 3-kinase α (PI3Kα), PI3Kγ, extracellular signal-regulated kinase (ERK), and phosphorylated ERK (p-ERK) in the adjacent zone of the MSC-treated group versus the MI-alone group. Moreover, the imbalance of the calcium-handling proteins sarcoplasmic reticulum Ca2+ adenosine triphosphatase (SERCA2a), phospholamban (PLB), and sodium/calcium exchanger type 1 (NCX-1) induced by MI was prevented by MSC transplantation, and more strikingly, the activity of SERCA2a and uptake of calcium were improved. In addition, the upregulation of the proapoptotic protein Bcl-xL/Bcl-2-associated death promoter (BAD) was normalized, as was phospho-Akt expression; there was less fibrosis, as revealed by staining for collagen; and the apoptosis of cardiomyocytes was significantly inhibited in the adjacent zone by MSC transplantation. Collectively, these data demonstrate that MSC implantation improved the remodeling in the region adjacent to the infarct after cardiac infarction in the ovine infarction model.

1 April 2013 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
XWXufeng Wei
Xufeng Wei
TLTieluo Li
Tieluo Li
BHBrian Hagen
Brian Hagen
PZPei Zhang
Pei Zhang
PSPablo G. Sanchez
Pablo G. Sanchez
BGBartley P. Griffith
Bartley P. Griffith

7 December 2012 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
MBMassimo Bernabei
Massimo Bernabei
RMRafik Margaryan
Rafik Margaryan
LALuigi Arcieri
Luigi Arcieri
Giacomo BianchiGiacomo Bianchi
Giacomo Bianchi
VPVitali Pak
Vitali Pak
BMBruno Murzi
Bruno Murzi
The incidence of recurrent aortic arch obstruction after Norwood procedure and other types of aortic arch reconstruction in newborns remains high. Biological and synthetic materials are used to enlarge the aorta. We report our experience using autologous pericardium to reconstruct the aortic arch in patients with hypoplastic left heart syndrome, aortic arch interruption and hypoplastic aortic arch. A retrospective analysis of 39 consecutively operated patients evaluated after an initial Norwood and other types aortic arch repair was performed. The presence of recurrent arch obstruction (mean gradient ≥20 mmHg) and its management were noted. The mean weight of our patients was 3.2 ± 0.7 kg. The mean age at primary surgical correction was 7.4 ± 6.8 (range 1–35 days). All patients were discharged without a significant residual gradient at the aortic arch except 4 who had a peak gradient of ≥30 mmHg. The overall incidence of recurrent arch obstruction was 28.2% (11 patients). Four (12.1%) patients had a distal obstruction, 1 (3%) had proximal obstruction and 1 had a mid-transverse arch obstruction. All patients underwent aortic arch reintervention consisting of balloon dilatation, and only after unsuccessful dilatation, 3 underwent surgical patch aortoplasties. The use of autologous pericardium in aortic arch reconstruction procedure is effective and associated with an acceptable incidence of recurrent arch obstruction. Its availability and characteristics make it an attractive alternative to other materials.